Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed Phase 1 Interventional

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

NCT04925687
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Intravitreal autologous CD34+ cells
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional

Response Inhibition Training for Children With Williams Syndrome

NCT02212314
View directory record Official record
Conditions
Williams Syndrome
Interventions
Response Inhibition Training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
10 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 31, 2026, 6:18 AM EDT
Completed No phase listed Observational

Alport Syndrome Treatments and Outcomes Registry

NCT00481130
View directory record Official record
Conditions
Alport Syndrome
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years to 99 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders

NCT02111200
View directory record Official record
Conditions
Urea Cycle Disorders, Inborn
Interventions
Sodium Benzoate, Sodium Phenylbutyrate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 31, 2026, 6:18 AM EDT
Recruiting No phase listed Observational

Study of Selected X-Linked Disorders: Aicardi Syndrome

NCT00697411
View directory record Official record
Conditions
Aicardi Syndrome, Brain Disorders
Interventions
Syndrome cause identification
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional

Qualitative Survey of Potential Exercise Activity in Adults With Sickle Cell Anemia (SCA)

NCT04181944
View directory record Official record
Conditions
Cardiovascular Diseases, Sickle Cell Disease, Exercise
Interventions
Exercise Treatment Group
Other
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

Eucrisa for Atopic Dermatitis

NCT03250663
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Online Treatment response, EUCRISA
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 31, 2026, 6:18 AM EDT
Terminated No phase listed Observational

Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique

NCT00384163
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 31, 2026, 6:18 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 31, 2026, 6:18 AM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
View directory record Official record
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 31, 2026, 6:18 AM EDT
Recruiting Not applicable Interventional

EHR Intervention to Increase HBOC Genetic Testing

NCT07876349
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Interventions
ELISABETH Evidence-Informed Program (EIP)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Misoprostol Ripening Efficacy With Dilapan

NCT03670836
View directory record Official record
Conditions
Labor Onset and Length Abnormalities, Induced; Birth
Interventions
Dilapan, Misoprostol
Device · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New York, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

NCT03432364
View directory record Official record
Conditions
Transfusion Dependent Beta-thalassemia
Interventions
ST-400 Investigational product
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 31, 2026, 6:18 AM EDT
Terminated No phase listed Observational

Kidney Information Network for Disease Research and Education

NCT03321604
View directory record Official record
Conditions
ESRD, Fabry Disease, Rare Diseases, Kidney Diseases, End Stage Renal Disease, Genetic Diseases, X-Linked
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Real-Time Functional Magnetic Resonance Imaging Neurofeedback to Improve Motor Function in Cerebellar Ataxia

NCT05436249
View directory record Official record
Conditions
Healthy
Interventions
Neurofeedback treatment, At-home therapy
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 31, 2026, 6:18 AM EDT
Recruiting No phase listed Observational

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

NCT06850038
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TRIV-509, Placebo
Drug
Lead sponsor
Triveni Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

NCT06149793
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Empagliflozin, Placebo Control
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional

Sleep and Pain in Sickle Cell Disease

NCT03150433
View directory record Official record
Conditions
Sickle Cell Disease, Sleep Disturbance, Pain
Interventions
Behavioral symptom management, Sickle cell disease management
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Duodenal Feeds in Very Low Birth Weight Infants

NCT04246333
View directory record Official record
Conditions
BPD - Bronchopulmonary Dysplasia, VLBW - Very Low Birth Weight Infant, Feeding Disorder Neonatal, Feeding; Difficult, Newborn, Premature Birth, Chronic Lung Disease of Prematurity
Interventions
Mode of Delivery of Feeds
Other
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Days to 12 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 31, 2026, 6:18 AM EDT
Completed Not applicable Interventional

Aerobic Exercise, Balance Training, and Ataxia

NCT03745248
View directory record Official record
Conditions
Ataxia, Spino Cerebellar Degeneration, Spinocerebellar Ataxias
Interventions
Aerobic training, Balance Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 31, 2026, 6:18 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 31, 2026, 6:18 AM EDT
Completed No phase listed Observational

Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

NCT02188758
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adults - CFPE Treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
South Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 31, 2026, 6:18 AM EDT